Bukwang Pharmaceutical Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jae-Young Lee

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	18.5yrs

Recente managementupdates

Recent updates

Bukwang Pharmaceutical (KRX:003000) Has Debt But No Earnings; Should You Worry?

Nov 13

Is Bukwang Pharmaceutical (KRX:003000) Weighed On By Its Debt Load?

May 22

Investors In Bukwang Pharmaceutical Co., Ltd. (KRX:003000) Should Consider This, First

Apr 03

Does It Make Sense To Buy Bukwang Pharmaceutical Co., Ltd. (KRX:003000) For Its Yield?

Dec 19

Did You Miss Bukwang Pharmaceutical's (KRX:003000) 90% Share Price Gain?

Nov 23

CEO

Jae-Young Lee

less than a year

Tenure

Jae-Young Lee is Chief Executive Officer of Bukwang Pharmaceutical Co. Ltd. from 2024.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sung-Gu Lee	President & Director	no data	geen gegevens	geen gegevens
Won-Tae Park	Managing Director and Director	18.5yrs	geen gegevens	geen gegevens
Sang-Hoon Kim	Senior Managing Director	no data	geen gegevens	geen gegevens
Dong-Yeon Kim	Chairperson	18.5yrs	geen gegevens	10.3% ₩ 32.2b
Chang-Soo Jung	Vice Chairman	18.5yrs	geen gegevens	geen gegevens
Yoo Hui-Won	Representative Director	no data	geen gegevens	geen gegevens
Sam-Moon Cho	Independent Outside Director	no data	geen gegevens	geen gegevens
Choon-Taek Yim	Independent Outside Director	no data	geen gegevens	geen gegevens
Young-Ho Song	Independent Outside Director	no data	geen gegevens	geen gegevens

18.5yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van A003000 zijn ervaren en ervaren (gemiddelde ambtstermijn van 18.5 jaar).

Bukwang Pharmaceutical Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Less than half of directors are independent

Bukwang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021

Recent updates

Bukwang Pharmaceutical (KRX:003000) Has Debt But No Earnings; Should You Worry?

New major risk - Financial data availability

Now 22% overvalued

Is Bukwang Pharmaceutical (KRX:003000) Weighed On By Its Debt Load?

H Delta Private Equity Partnership completed the acquisition of 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion.

H Delta Private Equity Partnership completed the acquisition of 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion.

Full year 2023 earnings released: ₩458 loss per share (vs ₩36.00 loss in FY 2022)

Second quarter 2023 earnings released: EPS: ₩7.00 (vs ₩6.00 loss in 2Q 2022)

Full year 2022 earnings released: ₩36.00 loss per share (vs ₩13.00 loss in FY 2021)

Upcoming dividend of ₩100.00 per share

Less than half of directors are independent

Bukwang Pharmaceutical Co., Ltd.(KOSE:A003000) dropped from KOSPI 200 Index

Less than half of directors are independent

Upcoming dividend of ₩90.91 per share

First quarter 2021 earnings released: ₩52.00 loss per share (vs ₩15.00 loss in 1Q 2020)

Investors In Bukwang Pharmaceutical Co., Ltd. (KRX:003000) Should Consider This, First

Full year 2020 earnings released: ₩115 loss per share (vs ₩114 loss in FY 2019)

Did Bukwang Pharmaceutical's (KRX:003000) Share Price Deserve to Gain 71%?

Bukwang Pharmaceutical Co., Ltd., Annual General Meeting, Mar 19, 2021

New 90-day low: ₩21,050

Is Bukwang Pharmaceutical (KRX:003000) A Risky Investment?

How Much Of Bukwang Pharmaceutical Co., Ltd. (KRX:003000) Do Insiders Own?

Does It Make Sense To Buy Bukwang Pharmaceutical Co., Ltd. (KRX:003000) For Its Yield?

New 90-day high: ₩32,350

Did You Miss Bukwang Pharmaceutical's (KRX:003000) 90% Share Price Gain?

New 90-day low: ₩23,000

New 90-day low: ₩26,700

New 90-day low: ₩32,850

New 90-day high - ₩41,550

CEO

Tenure

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd